BNP Paribas Financial Markets’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $618K | Buy |
51,549
+29,842
| +137% | +$248K | ﹤0.01% | 3640 |
|
|
2026
Q1 | $182K | Buy |
21,707
+8,697
| +67% | +$91.4K | ﹤0.01% | 4092 |
|
|
2025
Q4 | $187K | Sell |
13,010
-4,714
| -27% | -$58.8K | ﹤0.01% | 4083 |
|
|
2025
Q3 | $171K | Buy |
17,724
+2,800
| +19% | +$24.8K | ﹤0.01% | 4078 |
|
|
2025
Q2 | $123K | Sell |
14,924
-48,223
| -76% | -$404K | ﹤0.01% | 3947 |
|
|
2025
Q1 | $452K | Sell |
63,147
-32,946
| -34% | -$245K | ﹤0.01% | 3247 |
|
|
2024
Q4 | $743K | Buy |
96,093
+75,652
| +370% | +$710K | ﹤0.01% | 3027 |
|
|
2024
Q3 | $214K | Buy |
20,441
+17,533
| +603% | +$214K | ﹤0.01% | 3230 |
|
|
2024
Q2 | $34K | Sell |
2,908
-48,568
| -94% | -$756K | ﹤0.01% | 3546 |
|
|
2024
Q1 | $1.08M | Sell |
51,476
-16,284
| -24% | -$290K | ﹤0.01% | 2445 |
|
|
2023
Q4 | $1.22M | Buy |
67,760
+43,070
| +174% | +$759K | ﹤0.01% | 2278 |
|
|
2023
Q3 | $406K | Sell |
24,690
-10,890
| -31% | -$197K | ﹤0.01% | 2832 |
|
|
2023
Q2 | $711K | Sell |
35,580
-21,254
| -37% | -$409K | ﹤0.01% | 2398 |
|
|
2023
Q1 | $1.07M | Buy |
56,834
+27,338
| +93% | +$605K | ﹤0.01% | 2266 |
|
|
2022
Q4 | $669K | Sell |
29,496
-20,837
| -41% | -$471K | ﹤0.01% | 2406 |
|
|
2022
Q3 | $1.33M | Buy |
50,333
+39,703
| +373% | +$1.18M | ﹤0.01% | 2264 |
|
|
2022
Q2 | $263K | Sell |
10,630
-444
| -4% | -$11.1K | ﹤0.01% | 2972 |
|
|
2022
Q1 | $368K | Sell |
11,074
-8,885
| -45% | -$247K | ﹤0.01% | 2901 |
|
|
2021
Q4 | $653K | Sell |
19,959
-17,654
| -47% | -$601K | ﹤0.01% | 2866 |
|
|
2021
Q3 | $1.58M | Buy |
37,613
+25,167
| +202% | +$906K | ﹤0.01% | 2063 |
|
|
2021
Q2 | $484K | Buy |
12,446
+1,530
| +14% | +$54.7K | ﹤0.01% | 2551 |
|
|
2021
Q1 | $372K | Sell |
10,916
-53,391
| -83% | -$2.28M | ﹤0.01% | 2741 |
|
|
2020
Q4 | $2.92M | Buy |
64,307
+27,886
| +77% | +$974K | 0.01% | 1423 |
|
|
2020
Q3 | $1M | Sell |
36,421
-62,161
| -63% | -$2.03M | ﹤0.01% | 1809 |
|
|
2020
Q2 | $3.63M | Sell |
98,582
-23,179
| -19% | -$864K | 0.01% | 1217 |
|
|
2020
Q1 | $3.94M | Buy |
121,761
+8,925
| +8% | +$372K | 0.01% | 1095 |
|
|
2019
Q4 | $4.62M | Buy |
112,836
+106,854
| +1,786% | +$4.22M | 0.01% | 1242 |
|
|
2019
Q3 | $213K | Buy |
5,982
+1,589
| +36% | +$64.4K | ﹤0.01% | 2710 |
|
|
2019
Q2 | $226K | Sell |
4,393
-3,094
| -41% | -$154K | ﹤0.01% | 2542 |
|
|
2019
Q1 | $429K | Buy |
7,487
+6,076
| +431% | +$301K | ﹤0.01% | 2195 |
|
|
2018
Q4 | $59.2K | Sell |
1,411
-649
| -32% | -$38.1K | ﹤0.01% | 2632 |
|
|
2018
Q3 | $156K | Buy |
2,060
+322
| +19% | +$23.2K | ﹤0.01% | 2510 |
|
|
2018
Q2 | $125K | Sell |
1,738
-4,134
| -70% | -$197K | ﹤0.01% | 2673 |
|
|
2018
Q1 | $175K | Buy |
5,872
+261
| +5% | +$7.6K | ﹤0.01% | 2868 |
|
|
2017
Q4 | $187K | Buy |
5,611
+3,362
| +149% | +$101K | ﹤0.01% | 2996 |
|
|
2017
Q3 | $74.1K | Sell |
2,249
-604
| -21% | -$13.6K | ﹤0.01% | 2935 |
|
|
2017
Q2 | $56.3K | Buy |
2,853
+2,023
| +244% | +$39.2K | ﹤0.01% | 3131 |
|
|
2017
Q1 | $16K | Buy |
830
+547
| +193% | +$10.6K | ﹤0.01% | 3076 |
|
|
2016
Q4 | $5.25K | Sell |
283
-1,218
| -81% | -$23.3K | ﹤0.01% | 3686 |
|
|
2016
Q3 | $21K | Buy |
1,501
+711
| +90% | +$7.85K | ﹤0.01% | 2864 |
|
|
2016
Q2 | $6.32K | Buy |
790
+742
| +1,546% | +$8.23K | ﹤0.01% | 3147 |
|
|
2016
Q1 | $518 | Sell |
48
-1,268
| -96% | -$16.2K | ﹤0.01% | 2557 |
|
|
2015
Q4 | $21.8K | Buy |
+1,316
| New | +$26.1K | ﹤0.01% | 3260 |
|
Other funds holding RGNX
IHAM
BNP Paribas Financial Markets's RGNX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Regenxbio (RGNX) stake by 137% in Q2 2026, buying an estimated $248K and bringing the position to 51,549 shares worth $618K. The position accounts for ﹤0.01% of the portfolio, ranked #3640.
BNP Paribas Financial Markets first reported a position in RGNX in Q4 2015 and has held it in 43 quarters since. The position peaked at $4.62M in Q4 2019. 152 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- BNP Paribas Financial Markets held 51,549 shares of Regenxbio worth $618K as of Q2 2026.
- BNP Paribas Financial Markets bought 29,842 Regenxbio shares in Q2 2026, an estimated $248K.
- Regenxbio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3640 holding.
- BNP Paribas Financial Markets first reported a position in Regenxbio in Q4 2015 and has held it in 43 quarters since.
- BNP Paribas Financial Markets's Regenxbio position peaked at $4.62M in Q4 2019.
- 152 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.